SCHEMBL2904076

SCHEMBL2904076

Cc1ccccc1CN1CCN(C=CC(=O)c2ccccc2Cl)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
LMNA P02545 3/20 0.47
CXCR4 P61073 1/20 0.46
GAA P10253 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
CYP2A13 Q16696 1/20 0.44
FAAH O00519 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905724 0.90 FAAH (0.53) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL2906184 0.86 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL2904068 0.84 LMNA (0.51) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL2901992 0.83 KMT2A (0.46) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL2903101 0.81 SIGMAR1 (0.51) KMT2AMEN1ATMFAAH
SCHEMBL2907155 0.81 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL4379112 0.80 P2RX7 (0.53) ALDH1A1KDM4ELMNAMAPT
SCHEMBL2905103 0.80 F2R (0.57) KMT2AMEN1ATMFAAH
SCHEMBL2908298 0.79 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL2906083 0.78 SIGMAR1 (0.57) KMT2AMEN1ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PEREZ MICHEL (FR) 2012-09-13 US claimed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP claimed
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2009-07-09 US claimed
EP-2041104-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS Pierre Fabre Medicament (FR) 2009-04-01 EP claimed
WO-2007147824-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2007-12-27 WO claimed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 KMT2A 2861/4885MEN1 1701/4885ALDH1A1 1137/4885
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 KMT2A 2861/4885MEN1 1701/4885ALDH1A1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.